MAZE (Maze Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by MAZE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Harold Bernstein | President, R&D & CMO | Sell | — | — |
| 2026-09-04 | Phillips Courtney | GC and Corp. Secretary | Sell | — | — |
| 2026-09-04 | Atul Dandekar | CSBO | Sell | — | — |
| 2026-09-04 | Jason V Coloma | Chief Executive Officer | Sell | — | — |
| 2026-09-04 | Harold Bernstein | President, R&D & CMO | Sell | — | — |
| 2026-09-03 | Atul Dandekar | CSBO | M | — | — |
| 2026-09-03 | Harold Bernstein | President, R&D & CMO | MIXED | — | — |
| 2026-09-03 | Jason V Coloma | Chief Executive Officer | MIXED | — | — |
| 2026-09-03 | Phillips Courtney | GC and Corp. Secretary | M | — | — |
| 2026-08-31 | Atul Dandekar | CSBO | MIXED | — | — |
| 2026-08-17 | Sophie Kornowski | Director | A | — | — |
| 2026-08-17 | Paula A Johnson | Director | A | — | — |
| 2026-08-14 | Harold Bernstein | President, R&D & CMO | MIXED | — | — |
| 2026-08-05 | Jason V Coloma | Chief Executive Officer | Sell | — | — |
| 2026-07-31 | Atul Dandekar | CSBO | MIXED | — | — |
| 2026-07-02 | Harold Bernstein | President, R&D & CMO | MIXED | — | — |
| 2026-07-02 | Jason V Coloma | Chief Executive Officer | Sell | — | — |
| 2026-07-01 | Atul Dandekar | CSBO | MIXED | — | — |
| 2026-06-24 | Jason V Coloma | Chief Executive Officer | Sell | — | — |
| 2026-06-10 | Jonathan E Lim | Director | A | — | — |
| 2026-06-10 | CHARLES J HOMCY | Director | A | — | — |
| 2026-06-10 | RICHARD H SCHELLER | Director | A | — | — |
| 2026-06-10 | Nancy C Andrews | Director | A | — | — |
| 2026-06-10 | DANIEL K SPIEGELMAN | Director | A | — | — |
| 2026-06-10 | Herve Hoppenot | Director | A | — | — |
| 2026-06-03 | Jason V Coloma | Chief Executive Officer | Sell | — | — |
| 2026-06-03 | Harold Bernstein | President, R&D & CMO | MIXED | — | — |
| 2026-06-02 | Atul Dandekar | CSBO | MIXED | — | — |
| 2026-05-27 | Jason V Coloma | Chief Executive Officer | Sell | — | — |
| 2026-05-18 | Harold Bernstein | President, R&D & CMO | MIXED | — | — |
| 2026-05-18 | Jason V Coloma | Chief Executive Officer | Sell | — | — |
| 2026-05-06 | CHARLES J HOMCY | Director | G | — | — |
| 2026-05-06 | Atul Dandekar | CSBO | M | — | — |
| 2026-05-01 | Atul Dandekar | CSBO | MIXED | — | — |
| 2026-04-02 | Harold Bernstein | President, R&D & CMO | MIXED | — | — |
| 2026-04-02 | Amy Bachrodt | SVP, Finance | MIXED | — | — |
| 2026-04-01 | Atul Dandekar | CSBO | MIXED | — | — |
| 2026-03-20 | Harold Bernstein | President, R&D & CMO | MIXED | — | — |
| 2026-03-12 | Harold Bernstein | President, R&D & CMO | MIXED | — | — |
| 2026-03-03 | Jason V Coloma | Chief Executive Officer | A | — | — |
| 2026-03-03 | Misbah Tahir | Chief Financial Officer | A | — | — |
| 2026-03-03 | Harold Bernstein | President, R&D & CMO | A | — | — |
| 2026-03-03 | Atul Dandekar | CSBO | MIXED | — | — |
| 2026-03-03 | Phillips Courtney | GC and Corp. Secretary | A | — | — |
| 2026-03-03 | Amy Bachrodt | SVP, Finance | MIXED | — | — |
| 2026-02-04 | Amy Bachrodt | SVP, Finance | MIXED | — | — |
| 2026-02-04 | Harold Bernstein | President, R&D & CMO | MIXED | — | — |
| 2026-02-02 | Atul Dandekar | CSBO | MIXED | — | — |
| 2026-01-26 | Amy Bachrodt | SVP, Finance | MIXED | — | — |
| 2026-01-09 | Harold Bernstein | President, R&D & CMO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 7,024,758 | — |
| — | 10%+ Owner | 5,424,758 | — |
| — | Director | 328,700 | — |
| — | Chief Executive Officer | 45,642 | — |
| — | Director | 38,535 | — |
| — | CSBO | 35,950 | — |
| — | SVP, Finance | 13,265 | — |
| — | GC and Corp. Secretary | 7,029 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MAZE quote page; the site-wide leaderboard is on the insider transactions hub.